CollPlant Biotechnologies Ltd. (CLGN) — Analyst outlook / Analyst consensus target is. Based on 5 analyst ratings, the consensus is bullish — 4 Buy, 1 Hold.
The consensus price target is $12.50 (low: $11.00, high: $14.00), representing an upside of 3557.1% from the current price $0.34.
Analysts estimate Earnings Per Share (EPS) of $-0.29 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-1.45 vs est $-0.29 (missed -395.4%). 2025: actual $-0.94 vs est $-0.27 (missed -253.9%). Analyst accuracy: 24%.
CLGN Stock — 12-Month Price Forecast
$12.50
▲ +3,557.11% Upside
Average Price Target
Based on 5 Wall Street analysts offering 12-month price targets for CollPlant Biotechnologies Ltd., the average price target is $12.50, with a high forecast of $14.00, and a low forecast of $11.00.
The average price target represents a +3,557.11% change from the last price of $0.34.
Highest Price Target
$14.00
Average Price Target
$12.50
Lowest Price Target
$11.00
CLGN Analyst Ratings
Buy
Based on 5 analysts giving stock ratings to CollPlant Biotechnologies Ltd. in the past 3 months
EPS Estimates — CLGN
24%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$1.45
vs Est –$0.29
▼ 79.8% off
2025
Actual –$0.94
vs Est –$0.27
▼ 71.7% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — CLGN
37%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual $0.001B
vs Est $0.000B
▲ 76.3% off
2025
Actual $0.002B
vs Est $0.001B
▲ 49.9% off
Revenue Trend
Revenue has been relatively flat. Analysts forecast revenue contraction ahead.
